A Fibrose Cística (FC) é uma doença genética, até o momento incurável, que junto às demais condições crônicas, exigem cuidados que transcendem a esfera biológica da doença e do cuidado e necessita de estratégias inovadoras para seu manejo. Esse estudo teve por objetivo compreender o itinerário terapêutico de crianças com Fibrose Cística, a partir da perspectiva deles próprios. Para tanto, nos apoiamos no quadro teórico e metodológico conformado pela antropologia médica, etnografia e a hermenêutica interpretativa. Participaram do estudo, 7 crianças entre 8 a 10 anos, em tratamento em um hospital escola do interior do estado de São Paulo e seus familiares. Os dados foram coletados por quatro meses com cada criança partindo-se do referencial da etnografia, mediante observação participante, entrevistas e confecções de materiais que permitiram a participação infantil. Os resultados foram compreendidos em três atos interpretativos que conformam o círculo hermenêutico: As várias facetas da Fibrose Cística; Caminhos e cuidados: avaliações sobre o tratamento e Escolhas, caminhos e cuidados: o itinerário terapêutico de crianças com Fibrose Cística. A partir dos resultados, interpretamos que os modelos explicativos existentes na FC atualmente estão circunscritos em círculos concêntricos dentro dos setores e entre os diferentes atores envolvidos gerando avaliações fragmentadas e diferentes possibilidades de tratamento. As interpretações nos levaram a refletir a respeito da hegemonia do paradigma da saúde pautado no positivismo e suas implicações para o cuidado integral. As possibilidades de mudança aparecem ao considerarmos a etnografia e a hermenêutica enquanto referenciais para a prática bem como a centralidade e a potencialidade da criança como agente da mudança. / Cystic Fibrosis (CF) is a genetic disease which, along with other chronic conditions, calls for care that transcends the biological aspects of the disease and requires innovative strategies for its management. The aim of this study was to understand the therapeutic itinerary of children with cystic fibrosis through their point of view. To achieve this, we were supported by theoretical and methodological framework composed by medical anthropology, ethnography and interpretative hermeneutic. The participants were 7 children between the ages of 8 and 10 who were in treatment for CF at a University Hospital in the state of São Paulo and their relatives. Data were obtained during 4 months with each child using the ethnography method through participant observation, interviews and handmade materials that allowed children to participate. The results were understood in 3 interpretative acts that shaped the hermeneutic circle: Plenty faces of Cystic Fibrosis; Paths and care:treatment evaluations and Choices, paths and care: the therapeutic itinerary of children with Cystic Fibrosis. After analyzing the results, we interpreted that the explanatory models currently available in Cystic Fibrosis are limited in circles in the sectors and between the different actors involved what causes fragmented evaluations and different possibilities of treatment. Those interpretations lead us to reflect the hegemony of the health paradigm that is based on positivism and its implication for integral care. The possibilities of change appear when using the ethnography and the hermeneutic theories in the clinical practice and when considering the centrality and the potentiality of the children as transition agents.

Wang Xiaofei. / "June 2002." / Thesis (Ph.D.)--Chinese University of Hong Kong, 2002. / Includes bibliographical references (p. 152-167). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web. / Abstracts in English and Chinese.

In summary, the present findings have demonstrated the important roles of CFTR in prostatitis and cancer development, which may provide new insight into the understanding of the prostate in health and disease. The present findings may also have potential application in diagnosis and prognosis of cancer. / In the first part of the study, the possible role and a bacterial killing mechanism involving CFTR-mediated bicarbonate secretion in prostatitis were investigated in a rat prostate model. CFTR was found to be expressed in the epithelium of rat ventral prostate. Experiments using cultured rat primary prostate epithelial cells demonstrated that CFTR was involved in mediating bicarbonate extrusion across the prostate epithelium. The expression of CFTR and carbonic anhydrase II (CAII), a key enzyme involved in cellular HCO 3- production, along with several pro-inflammatory cytokines including IL-6, IL-1beta, TNF-alpha, was significantly up-regulated in the primary culture of rat prostate epithelial cells upon E.coli-LPS challenge. Inhibition of CFTR function in vitro or in vivo resulted in reduced bacterial killing by prostate epithelial cells or the prostate. High HCO3- content (>50mM), rather than alkaline pH, was found to be responsible for bacterial killing. The direct action of HCO 3- on bacterial killing was confirmed by its ability to suppress bacterial initiation factors in E coli. The relevance of the CFTR-mediated HCO3- secretion in human was demonstrated by the upregulated expression of CFTR and CAII in human prostatitis tissues. The present results have demonstrated that CFTR plays a previously undefined role in prostatitis and could be up-regulated during the inflammation in prostate as a host defense mechanism to increase bicarbonate secretion for bacterial killing. / In the second part of the study, the possible role of CFTR in prostate cancer development and the underlying mechanisms were investigated. Our results showed that the expression of CFTR and CAII in prostate was remarkably decreased in aged rat prostate. We observed that testosterone could up-regulate the expression of CFTR and CAII in vitro and in vivo , indicating that the declined male hormones during aging may be responsible for the observed age-dependent expression of CFTR. In the present study, we found that inhibition of CFTR enhanced cell proliferation/anti-apoptosis in the prostate primary epithelial cells. CFTR was detected in all examined prostate cell lines, but with relatively higher expression levels in immortalized cell lines (PZ-HPV-7, PNT1A, PNT2C2) than in cancer cell lines (PC-3, DU-145, LNCaP). Immunohistological studies showed that the expression of CFTR was dramatically reduced in prostate cancer specimens as compared to that in normal prostate tissues. Furthermore, our gain and loss of function studies showed that knockdown of CFTR profoundly enhanced cell proliferation, cell adhesion, invasion and migration, while inhibited apoptosis in prostate cancer cell lines, overexpression of CFTR dramatically suppressed tumorigenic phenotype of cancer cells. Soft agar anchorage-independent growth assay showed that knockdown of CFTR in prostate cancer cells increased the number of colonies formed in soft agar. More importantly, we demonstrated that CFTR knockdown promoted the tumor growth in vivo and forced overexpression of CFTR in prostate cancer cells and ultrasound-mediated gene transfer of CFTR inhibited xenograft tumor growth in vivo. Mechanistically, multiple mechanisms were identified to contribute to the CFTR- mediated tumor suppressive effects. Firstly, CFTR chloride channel function was implicated in the regulation of apoptosis in prostate cancer cells. Secondly, CFTR up-regulated the transcription level of miR-34a and miR-193b, both of which have been indicated as tumor suppressors in multiple cancers. Thirdly, 11 cancer-related genes were found to be up- or down-regulated by CFTR using PCR-array. These data demonstrated that CFTR may play an important role in prostate cancer development by acting as a tumor suppressor. / The cystic fibrosis transmembrane conductance regulator (CFTR) is an anion channel conducting both Cl- and HCO3 -. It is expressed in epithelial cells of a wide variety of tissues. CFTR is also known to be expressed in human prostate; however, the physiological role of CFTR in the prostate and related diseases remains largely unknown. This thesis explored the biological roles of CFTR in prostatitis and cancer development. / Xie, Chen. / Adviser: Chan LiShaw Chang. / Source: Dissertation Abstracts International, Volume: 73-02, Section: B, page: . / Thesis (Ph.D.)--Chinese University of Hong Kong, 2010. / Includes bibliographical references (leaves 175-192). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [201-] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese.

Mutations in the eukaryotic integral membrane protein Cystic Fibrosis Transmembrane conductance Regulator (CFTR) cause the hereditary disease cystic fibrosis (CF). CFTR functions as an ion channel at the surface of epithelial cells and regulates the movement of chloride ions and water across the plasma membrane. CFTR is difficult to express and purify in heterologous systems due to its propensity to form insoluble aggregates and its susceptibility to degradation. Obtaining good yields of highly purified CFTR has proven problematic and contributes to our limited understanding of the structure and function of the protein. The most prevalent disease causing mutation, F508del, results in misfolded CFTR which is particularly unstable and is quickly targeted for degradation by the host system and is prevented from being trafficked to the plasma membrane. There are limited treatment options for patients with the F508del mutation and it is therefore of significant interest within CF research. New methods and assays are required to identify potential compounds which could correct the F508del mutation. This thesis investigates the use of Saccharomyces cerevisiae to express and purify codon optimised recombinant CFTR. The use of a green fluorescent protein (GFP) tag enabled quick and simple detection of CFTR in whole cells and after extraction from the plasma membrane. By optimising the culture conditions for CFTR expression and detergent solubilisation conditions, relatively high yields of full-length protein were obtained. When used as a chemical chaperone at the time of inducing CFTR expression, glycerol increased yields of full-length protein. Degradation of CFTR could be limited by inducing expression at an optimal cell density and by harvesting cells within a specific time window. CFTR was extracted by solubilisation in the mild detergent dodecyl-β-D-maltopyranoside (DDM) in the presence of up to 1 M NaCl with up to ~87% efficiency in some cases. Using a gene optimisation strategy in which additional purification tags and a yeast Kozak-like sequence were added, the human CFTR (hCFTR) protein was expressed and purified. Fluorescence microscopy revealed CFTR localisation at the periphery of yeast cells. Immunoaffinity chromatography facilitated by the GFP tag at the C terminus of CFTR produced protein of up to 95% purity. An assessment of the thermal stability of this highly purified CFTR using a fluorescent probe binding assay revealed a denaturation midpoint (Tm) of ~43 degC. The ability of this assay to determine the stability of CFTR is encouraging and there is the potential to further develop it in a high-throughput manner to identify compounds which stabilise the F508del protein and which may hold the key to developing new treatments for CF.

A Fibrose Cística (FC) é uma doença hereditária sendo a pneumopatia obstrutiva crônica e a insuficiência pancreática suas manifestações clínicas mais clássicas. Exige um controle intenso e tratamento crônico e complexo que envolve a utilização de diversos medicamentos e procedimentos. O diagnóstico afeta a estrutura e altera a dinâmica de uma família. E o cuidado com o paciente geralmente recai sobre um único familiar que chamamos de cuidador principal. Conhecer aspectos qualitativos e quantitativos do consumo dos medicamentos, os hábitos dos pacientes e de seus cuidadores, pode influenciar diretamente no curso da doença. Objetivo: Caracterizar a utilização de medicamentos de pacientes fibrocísticos, caracterizar tanto pacientes quanto cuidadores, além de identificar as dificuldades existentes no cumprimento do plano terapêutico medicamentoso. Métodos: Estudo transversal com análise dos prontuários e entrevista do farmacêutico com o cuidador de pacientes com FC, acompanhados em um centro de referência de um hospital de ensino. Foram coletadas informações sobre a clínica dos pacientes, informações gerais sobre os cuidadores, assim como informações sobre o entendimento da doença, os medicamentos em uso e forma de utilização do tratamento em domicilio. Resultados: Foram analisados os dados de 78 pacientes e entrevistados 75 cuidadores. Maioria dos pacientes foi do sexo feminino, branca, homozigota para F508del, eutrófica e procedente do interior do Estado. Entre os cuidadores, a maioria também era do sexo feminino, mãe do paciente e não trabalhava fora do domicílio. Foi possível verificar a utilização de polifarmacoterapia e regimes terapêuticos complexos no tratamento da FC, além de dificuldades referentes à aquisição de medicamentos e em relação ao restante do tratamento, mesmo sendo observado o bom entendimento sobre a doença e da utilização dos medicamentos na maioria dos cuidadores. Conclusões: Os estudos de utilização de medicamentos permitem que conheçamos a dinâmica do tratamento, o funcionamento e as necessidades do paciente e de sua rede de apoio, planejando ações e intervindo com o objetivo de contribuir para o bem estar das crianças e adolescentes fibrocísticos e de seus cuidadores. / Cystic Fibrosis is a hereditary disease being the pneumopathies chronic obstructive and the pancreatic failure its clinical manifestations. This disease demands a high control and a complex treatment. The diagnosis affects the structure and changes a family routine. The patient caring usually relies on only one family member that we understand as the main caregiver. The knowledge of qualitative and quantitative aspects of medicines consumption, besides the patients’ their caregivers’ routines may directly affect the development of the disease. Objective: To describe the use of medicines by Cystic Fibrosis patients, outlining the patients and the caregivers profile, as well as identifying difficulties existing in the medication therapeutic plan fulfillment. Methods: Cross-sectional study through the analysis of medical records and interviews conducted by the pharmacist with caregivers of cystic fibrosis patients accompanied in a reference center of a teaching hospital. The study collected clinical information about the patients, general information about the caregivers and also information about the understanding of the disease, the medicines in use and the ways of utilization of treatment at home. Results: The study analyzed data from 78 patients and 75 caregivers were interviewed. Most of the patients were female, white, homozygotic for F508del, eutrophic and from the state’s countryside. Among the caregivers, most of them were female, patient’s mother and not working out of home. It was possible to verify the use of polypharmacotherapy and complex therapeutic regimes on the treatment of cystic fibrosis, besides the difficulties regarding the purchase of medicines and also regarding the rest of the treatment, even observed the knowledge about the disease and about the use of medicines in the most of the caregivers. Conclusions: The studies about the use of medicines allow us to know the dynamic of the treatment, the evolution and the needs of the patients and their supporting network, planning actions and interfering with the purpose to contribute with the well-being of the cystic fibrosis children and adolescents and their caregivers.

Introdução: A Fibrose Cística (FC) é uma doença autossômica recessiva letal, se manifesta como uma síndrome clínica multissistêmica e progressiva. A expectativa de vida dos pacientes vem aumentando nos últimos anos, o que consequentemente acarreta em maior carga de tratamento. Esta realidade vem demandando das equipes multidisciplinares uma maior atenção relacionada a educação em saúde e a adesão do paciente ao tratamento. Objetivos: Avaliar adesão ao tratamento, qualidade de vida, conhecimento sobre o manejo doença antes e após intervenção educacional em pacientes com FC. Materiais e Métodos: Estudo tipo coorte prospectiva. População: crianças e adolescentes com diagnóstico médico de FC, idade entre 6 e 18 anos e em acompanhamento no ambulatório. Entre critérios de exclusão a incapacidade motora de realizar os testes propostos, ter perspectiva de transplante pulmonar durante o período do estudo ou não completar os cinco encontros propostos. Pacientes foram submetidos a um plano educacional de um ano em cinco encontros. Os encontros ocorriam paralelos à consulta de rotina onde foi entregue um informativo ao paciente e realizado conversa sobre tópicos do tratamento. Na avaliação inicial foi coletado de prontuário dados antropométricos, espirometria e aplicado: Teste de Caminhada dos 6 Minutos (TC6M), instrumento de auto relato de adesão ao tratamento, questionário de conhecimento sobre o manejo da doença e questionário de qualidade de vida na FC. Além disso, foi realizada a primeira abordagem educacional: Aspectos gerais sobre a FC. Nos encontros 2, 3 e 4 os temas: Fisioterapia Respiratória; Nutrição; Atividade Física. No encontro 5 foi realizada a reavaliação. Análise Estatística, os dados foram expressos em média e desvio padrão e frequência absoluta e percentual. Foi realizado teste t pareado para pré e pós-intervenção. O nível de significância foi de p<0,05. O programa estatístico: SPSS 18.0. Resultados: Amostra composta por 17 crianças e adolescentes com média de idade de 10,9 anos (±2,2) apresentando escore-z do IMC, função pulmonar e distância percorrida no TC6M dentro dos padrões de normalidade para a idade. Para adesão ao tratamento houve melhora no domínio atividade física e no total do tratamento. Para a qualidade de vida houve piora significativa para os domínios: alimentação, carga de tratamento, emocional e social. Sobre o conhecimento da doença para responsáveis e pacientes não houve significância. Conclusão: Intervenção educacional melhora adesão ao tratamento da FC na atividade física, bem como ao tratamento total da doença. Houve diminuição do número de internações. Limite pequeno tamanho amostral. / Introduction: The cystic fibrosis (CF) is an disorder autosomal recessive lethal, manifests as a clinical syndrome multisystem and progressive. The life expectancy of patients has been increasing in recent years, which consequently results in a higher burden of treatment. This reality has been demanding of multidisciplinary teams greater attention related to health education and patient adherence to treatment Objectives: To evaluate treatment adherence, quality of life, knowledge about the management of disease before and after educational intervention in patients with Cystic Fibrosis (CF). Materials and Methods: Study prospective cohort. Population: children and adolescents with a diagnosis of CF, aged 6 to 18 years and followed up at the outpatient clinic. Among exclusion criteria motor incapacity to perform the proposed tests have perspective lung transplant during the study period or not complete the five proposed meetings. The meetings took place parallel to the routine consultation which received an information to the patient and held discussion on topics of treatment. In the initial evaluation was collected from medical records anthropometric data, spirometry and applied: Walk Test 6 Minutes (WT6M), instrument self-accession report to treatment, knowledge questionnaire on the management of the disease and quality of life questionnaire in FC. Furthermore, the first educational approach was taken: General Aspects of FC. In meetings 2, 3 and 4 themes: Respiratory Physiotherapy; Nutrition; Physical activity. At the meeting 5 was realized the revaluation. Statistical Analysis Data were expressed as mean and standard deviation and absolute and percentage frequency. Paired t test was performed for pre- and post-intervention. The level of significance was set at p <0.05. The statistical software: SPSS 18.0. Results: A sample of 17 children and adolescents with a mean age of 10.9 years (± 2.2) presenting z-score of BMI, lung function and distance in TC6M within the normal range for age. For adherence to treatment there was an improvement in physical activity domain and the total treatment. For the quality of life was significantly worse for the areas: food, loading treatment, emotional and social. About knowledge of the disease to responsible and patients was not significant. Conclusion: Educational intervention improves adherence to treatment of CF in physical activity, and the overall treatment of the disease. There was a decrease in the number of hospitalizations. Limit small sample size.

Tsang Lai-Ling Angel. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2001. / Includes bibliographical references (leaves 136-145). / Abstracts in English and Chinese. / Abstract --- p.i / 論文撮要 --- p.iv / Acknowledgment --- p.vi / Table of Content --- p.vii / List of Publications --- p.xii / List of Figures --- p.xiv / List of Tables --- p.xvii / Abbreviations --- p.xviii / Chapter Chapter1 --- Introduction --- p.1 / Chapter 1.1 --- The Human Uterus Vs Rat Uterus --- p.1 / Chapter 1.1.1 --- Myometrium --- p.1 / Chapter 1.1.2 --- Endometrium --- p.1 / Chapter 1.2 --- The Human Endometrium Vs Rat Endometrium --- p.2 / Chapter 1.2.1 --- The structure of Human Endometrium --- p.2 / Chapter 1.2.2 --- Cyclic Changes in the Endometrium --- p.4 / Chapter 1.2.3 --- Physiological Roles of the Endometrium --- p.7 / Chapter 1.2.4 --- Uterine Fluid Volume and its Composition --- p.7 / Chapter 1.2.4.1 --- Regulation of Uterine Fluid Volume and Composition --- p.7 / Chapter 1.2.4.2 --- Role of Endometrial Epithelium in the Regulation of Uterine Fluid Volume --- p.9 / Chapter 1.3 --- Epithelial Ion Channels --- p.9 / Chapter 1.3.1 --- Epithelial CI- Channels in Secretory Epithelia --- p.11 / Chapter 1.3.1.1 --- Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) --- p.13 / Chapter 1.3.2 --- Epithelial Na+ Channel (ENaC) in Absorbing Epithelia --- p.18 / Chapter 1.3.3 --- ENaC and CFTR in Endometrial Epithelia --- p.26 / Chapter 1.4 --- Hormonal Regulation of the Endometrial Epithelium --- p.29 / Chapter 1.4.1 --- Estrogen and Progesterone --- p.29 / Chapter 1.4.2 --- Aldosterone --- p.32 / Chapter 1.5 --- Aim of Study --- p.35 / Chapter Chapter2 --- Materials and Methods --- p.38 / Chapter 2.1 --- Materials --- p.38 / Chapter 2.1.1 --- Culture Medium and Enzymes --- p.38 / Chapter 2.1.2 --- Drugs --- p.38 / Chapter 2.1.3 --- Molecular Biology --- p.39 / Chapter 2.1.4 --- Experimental Tissues and Animals --- p.39 / Chapter 2.2 --- Preparations --- p.39 / Chapter 2.2.1 --- Pervious Support for Cell Growth --- p.39 / Chapter 2.2.2 --- Growth Medium --- p.40 / Chapter 2.2.3 --- Culture of Mouse Endometrium Epithelial Cells --- p.43 / Chapter 2.2.4 --- Solutions for the Short-Circuit Current Measurement --- p.44 / Chapter 2.2.5 --- Electrodes for the Short-Circuit Current Measurement --- p.44 / Chapter 2.2.6 --- Solutions for Molecular Biology Experiment --- p.44 / Chapter 2.2.6.1 --- Diethyl Pyrocarbonate (DEPC)-treated Water --- p.44 / Chapter 2.2.6.2 --- lx TAE (DNA gel electrophoresis and its running buffer) --- p.45 / Chapter 2.2.6.3 --- 5x MOPS (RNA gel electrophoresis and its running buffer) --- p.45 / Chapter 2.2.6.4 --- Formaldehyde Gel-loading Buffer --- p.45 / Chapter 2.3 --- Protocols --- p.46 / Chapter 2.3.1 --- Effect of Ovarian Hormones and Aldosterone on CFTR and ENaC Expression --- p.45 / Chapter 2.3.2 --- Possible Interaction between CFTR and ENaC upon Hormones Stimulation --- p.47 / Chapter 2.4 --- Methods of Measurement --- p.48 / Chapter 2.4.1 --- The Short-Circuit Current Technique --- p.48 / Chapter 2.4.1.1 --- The Short-Circuit Current Setup --- p.48 / Chapter 2.4.1.2 --- Experimental Procedures --- p.52 / Chapter 2.4.1.3 --- Data Analysis --- p.55 / Chapter 2.4.2 --- Reverse Transcription - Polymerase Chain Reaction (RT-PCR) --- p.55 / Chapter 2.4.2.1 --- RNA Isolation --- p.55 / Chapter 2.4.2.2 --- RNA Gel Electrophoresis --- p.56 / Chapter 2.4.2.3 --- Reverse Transcription (RT) --- p.57 / Chapter 2.4.2.4 --- Primer used for the Polymerase Chain Reaction (PCR) --- p.58 / Chapter 2.4.2.5 --- General Procedure of PCR and Competitive RT-PCR --- p.59 / Chapter 2.4.2.6 --- DNA Gel Electrophoresis --- p.61 / Chapter 2.4.3 --- Capillary Electrophoresis - Laser Induced Fluorescence (CE-LIF) --- p.62 / Chapter 2.4.3.1 --- Capillary Tube --- p.54 / Chapter 2.4.3.2 --- Detection System --- p.65 / Chapter 2.4.3.3 --- Experimental Procedures --- p.65 / Chapter 2.4.3.4 --- Data Analysis --- p.66 / Chapter 2.4.4 --- Statistical Analysis / Chapter Chapter3 --- Results --- p.68 / Chapter 3.1 --- Influence of Ovarian Hormones on Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and Epithelial Na+ Channel (ENaC) Expression in Mouse Endometrial Epithelium --- p.68 / Chapter 3.2 --- Culture Condition on Expression and Function of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in Mouse Endometrial Epithelial Cells --- p.92 / Chapter 3.3 --- Expression Regulation of Endometrial Epithelial Na+ Channel (ENaC) Subunits and Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) by Na+ Diet During the Estrus Cycle in Mice --- p.98 / Chapter 3.4 --- Enhanced Epithelial Na+ Channel (ENaC) Activity in Mouse Endometrial Epithelium by Upregulation of γ-ENaC Subunit --- p.114 / Chapter Chapter4 --- General Discussion --- p.127 / Appendix --- p.132 / Chapter A. --- RNA Isolation --- p.132 / Chapter B. --- Reverse Transcription (RT) --- p.133 / Chapter C. --- Polymerase Chain Reaction (PCR) --- p.134 / Chapter D. --- Sequences and Conditions of All Primers --- p.135 / References --- p.136

O Complexo Burkholderia cepacia (CBc) é um grupo de 17 espécies intimamente relacionadas que estão associadas à deterioração pulmonar e aumento da mortalidade em pacientes com Fibrose Cística (FC). Essas espécies variam entre si em relação à prevalência, quadros clínicos e virulência. Pouco é conhecido em relação ao perfil de resistência aos antimicrobianos. Uma vez estabelecida a infecção, a abordagem terapêutica e as medidas de controle atualmente adotadas são baseadas no CBc, sem considerar cada espécie em particular. O objetivo deste estudo foi determinar a prevalência das espécies do CBc em pacientes atendidos em dois centros de referência no Rio de Janeiro, bem como estabelecer perfis de resistência a antimicrobianos e avaliar a diversidade molecular entre as espécies. Cem amostras do CBc isoladas de 38 pacientes com FC no período de janeiro de 2010 a fevereiro de 2012 foram identificadas por métodos fenotípicos e pelo sequenciamento do gene recA. As CIMs para amicacina, aztreonam, ceftazidima, trimetoprim/sulfametoxazol e tobramicina foram determinadas por microdiluição e a genotipagem das espécies foi realizada por PFGE com a enzima SpeI. B. vietnamiensis (44%) foi a espécie mais prevalente, seguida de B. cenocepacia IIIA (36%), B. multivorans (10%), B. cenocepacia IIIB (1%) e B. stabilis (1%). Cinco por cento das amostras não foram identificadas. B. vietnamiensis foi identificada em mais da metade dos pacientes (58,3%). Foram observadas diferenças no perfil de susceptibilidade entre as espécies do CBc. B. cenocepacia IIIA foi a espécie que apresentou as maiores taxas de resistência aos antimicrobianos, sobretudo para trimetoprim/ sulfametoxazol (80,5%), principal antimicrobiano utilizado no tratamento de infecções causadas pelo CBc. Amostras com perfis MDR ocorreram em todas as espécies, destacando-se o perfil A, resistente simultaneamente aos cinco antimicrobianos, observado em 58,8% das amostras de B.cenocepacia IIIA. A análise do polimorfismo genético mostrou que, apesar de B. vietnamiensis ter sido a espécie mais prevalente, a ocorrência de nove grupos clonais sugere que a aquisição dessas cepas tenha se dado a partir de uma fonte ambiental comum. Para B. cenocepacia IIIA, 52,9% das amostras foram atribuídas a um mesmo grupo clonal (BcA), compartilhado entre nove pacientes atendidos em um mesmo centro de referência. Oitenta por cento dessas amostras apresentaram ainda resistência a todos os antimicrobianos testados. Os dados mostram que, mesmo com o emprego de técnicas moleculares, é difícil a identificação do CBc em nível de espécie; que B. cenocepacia IIIA é caracterizada por índices de resistência superiores às outras espécies e que a transmissão cruzada entre os indivíduos aponta para a necessidade do estabelecimento de medidas de vigilância do CBc nos centros de referência. / The Burkholderia cepacia complex (BCC) is a group of 17 closely related species that are associated with pulmonary deterioration and increased mortality in patients with Cystic Fibrosis (CF). These species differ from each other in prevalence, clinical status and virulence. Little is known about the profile of antimicrobial resistance. Once the infection, the therapeutic approach and the control measures currently adopted are based on BcC, without considering each particular species. The aim of this study was to determine the prevalence of BcC species in patients from two reference centers in Rio de Janeiro, as well as establishing antimicrobial resistance profiles and assess the molecular diversity among them. One hundred samples of BcC isolates from 38 CF patients from January 2010 to February 2012 were identified by phenotypic methods and by sequencing the recA gene. The MIC for amikacin, aztreonam, ceftazidime, trimethoprim /sulfamethoxazole and tobramycin were determined by microdilution species and genotyping was carried out by PFGE with the enzyme SpeI. B. vietnamiensis (44%) was the most prevalent species, followed by B. cenocepacia IIIA (36%), B. multivorans (10%), B. cenocepacia IIIB (1%) and B. stabilis (1%). Five percent of the samples were not identified. B. vietnamiensis was identified in over half of patients (58.3%). There were differences in susceptibility profiles among BcC species. B. cenocepacia IIIA showed the highest rates of antimicrobial resistance, particularly to trimethoprim/ sulfamethoxazole (80.5%), primary antimicrobial used to treat infections caused by BcC. Samples with MDR profiles were observed for all species, highlighting the profile A, simultaneously resistant to five antibiotics, observed in 58.8% of B.cenocepacia IIIA samples. The analysis of genetic polymorphism showed that despite B. vietnamiensis was the most prevalent species, the occurrence of nine clonal groups suggests that these strains acquisition has taken place from a common environmental source. For B. cenocepacia IIIA, 52.9% of the samples were assigned to the same clonal group (BcA), shared among nine patients treated at a single referral center. Eighty percent of these samples also showed resistance to all antimicrobials tested. The data show that, even with the use of molecular techniques, the identification of BcC on species level is difficult; that B. cenocepacia IIIA is characterized by higher levels of resistance to other species and that the cross transmission between individuals points to the need for the establishment of BcC surveillance in reference centers.

INTRODUÇÃO: apesar da identificação de mais de 1500 mutações para o gene CFTR (cystic fibrosis transmembrane conductance regulator), o teste do suor ainda é o teste diagnóstico para Fibrose Cística (FC). O teste quantitativo de iontoforese por pilocarpina (TQIP) é o padrão-ouro para coleta do suor e análise do cloro, mas está sujeito a erros se não for realizado por técnicos qualificados. Embora a técnica de coleta do suor pelo sistema macroduct® e análise pela condutividade seja simples e tenha boa correlação com os níveis de cloro em estudos prévios, a mesma ainda é considerada como um teste de triagem para FC. O melhor ponto de corte para confirmar ou afastar a FC pelo método da condutividade deve ser ainda estabelecido. OBJETIVOS: comparar os valores de cloro no suor obtidos pelo teste quantitativo da iontoforese pela pilocarpina (teste clássico) com os valores de condutividade do suor obtido pelo sistema de coleta por macroduct® (teste simplificado) em pacientes com e sem FC e em uma amostra aleatória de pacientes em investigação para FC. O custo e o tempo despendidos na execução de cada teste foram também analisados na fase inicial do estudo. MÉTODOS: o teste do suor, pelas duas técnicas, foi realizado simultaneamente em pacientes com e sem FC e posteriormente em pacientes em investigação diagnóstica da doença no período de fevereiro/2006 a outubro/2008. Os pontos de corte para a condutividade para excluir ou diagnosticar FC foram < 75 e ? 90 mmol/L, respectivamente, e para o teste clássico cloro ? 60 e > 60 mmol/L. Na fase inicial da pesquisa (casos com e sem FC) foram utilizadas tabelas de contingência para os cálculos de sensibilidade (S), especificidade (E), valor preditivo positivo (VPP) e negativo (VPN), além do teste exato de Fisher para avaliar a associação entre os testes e a presença ou ausência de FC. Na amostra aleatória de pacientes usou-se a curva ROC também para os cálculos de S, E, VPP e VPN e também para calcular a área sob a curva entre os testes, e, em ambas as fases da pesquisa, para avaliar sua acurácia. Os respectivos intervalos de confiança de 95% (IC95%) também foram analisados. Para avaliação da concordância entre os testes, na amostra aleatória de pacientes, utilizou-se o coeficiente de kappa e o teste de McNemar. Aplicou-se o teste de Wilcoxon para se comparar os tempos na execução de cada teste, sendo considerados significativos quando p<0,05. RESULTADOS: 52 pacientes com FC (29M/23F; 1,5 a 18,2 anos) realizaram o teste do suor pelas duas técnicas, apresentando valores medianos de cloro e condutividade no suor de 114 e 122 mmol/L, respectivamente. A condutividade foi ? 95 mmol/L em todos os pacientes, conferindo ao teste 100% de sensibilidade (IC95%: 93,1 a 100%). Cinquenta pacientes sem FC (24M/26F; 0,5 a 12,5 anos) apresentaram valores medianos de cloro e condutividade no suor de 15,5 e 30 mmol/L, respectivamente. Em todos os casos a condutividade foi < 70 mmol/L, conferindo ao teste 100% de especificidade (IC95%: 92,9 a 100%). Foram então realizados 918 testes nos pacientes em investigação para FC, mas, em 180, as amostras foram inadequadas. Dos 738 testes realizados pelas duas técnicas, em 714 pacientes se afastou a FC, encontrando-se mediana de cloro de 11 mmol/L (variação: 3 a 137 mmol/L) e de condutividade de 25 mmol/L (variação: 14 a 138 mmol/L). Foram confirmados 24 pacientes com FC, encontrando-se uma mediana de cloro de 87 mmol/L (variação: 54 a 132 mmol/L) e de condutividade de 103 mmol/L (variação: 50 a 126 mmol/L). Pela curva ROC, com valores de condutividade > 90 mmol/L, obteve-se S= 83,3%, E= 99,7%, VPP= 90,9% e VPN= 99,4% para o diagnóstico de FC. Com valores de condutividade < 75 mmol/L praticamente se pôde excluir o diagnóstico de FC (VPN=99,7%; IC95%:99,0-100%). Houve excelente concordância entre o teste clássico e o simplificado, tanto pelo valor de kappa (0,934; IC95% 0,86 a 1,009), quanto pelo teste de McNemar (p=1,0000). O tempo despendido na execução dos testes foi significativamente menor com o teste simplificado (p<0,0001) e o custo do método simplificado foi discretamente inferior. CONCLUSÕES: o teste da condutividade do suor, seja em pacientes com diagnóstico previamente conhecido (com ou sem FC) ou quando realizado aleatoriamente, mostrou resultados superponíveis ao teste clássico e foi capaz de diferenciar pacientes com e sem FC. O teste simplificado apresentou alta sensibilidade e especificidade e houve excelente concordância entre os testes. O tempo de execução foi mais rápido e o custo inferior ao teste clássico. / INTRODUCTION: despite the identification of over 1500 CFTR (cystic fibrosis transmembrane conductance regulator) gene mutations, the sweat test is still the diagnostic test for cystic fibrosis (CF). The quantitative pilocarpine iontophoresis test (QPIT) is the gold-standard method for collection of sweat and chloride analyses, but is subjected to errors if not performed by qualified technicians. Although the technique using the macroduct system for sweat collection and the conductivity analysis is simpler and has good correlation with chloride levels in previous studies, it is still considered a screening test for CF. The best cut-off point of sweat conductivity to confirm or rule out CF must yet be established. OBJECTIVES: to compare the sweat chloride values obtained by the quantitative pilocarpine iontophoresis test (classic test) with sweat conductivity analysis obtained by the macroduct (simplified test) in patients with a confirmed CF diagnosis, in patients without CF and in a random sample of patients being investigated for CF. The cost and time spent to perform each test were also analysed in the initial phase of the study. METHODS: both techniques of sweat test were simultaneously performed initially in patients with CF, afterwards in patients in whom CF had been ruled out and finally in patients referred for a sweat test between February 2006 and October 2008. The cut-off values for sweat conductivity to exclude or diagnose CF were = 90 mmol/L and for the QPIT were sweat chloride ? 60 e > 60 mmol/L, respectively. Contingency tables were used in the initial phase of the study (cases with or without CF) for calculation of sensitivity (Se), specificity (Sp), positive (PPV) and negative predictive value (NPV) and Fisher\'s exact test was used to assess the association between the tests and the presence or absence of CF. ROC curve was used in the random sample of patients also for calculation of Se, Sp, PPV and NPV and also to calculate the area under the curve between both tests in both phases of the study to assess their accuracy. The respective 95% confidence intervals (95%CI) were also analysed. Kappa coefficient and McNemar tests were used for evaluation of agreement between the tests in the random sample of patients. Wilcoxon test was used to compare the time spent to perform each test, with the significant difference set at p < 0.05. RESULTS: in 52 CF patients (29M/23F, age range 1.5 to 18.2y) the median value of sweat Cl and conductivity were 114 and 122 mmol/L, respectively. All patients had sweat conductivity values above 95 mmol/L (100% sensitivity; 95%CI: 93.1 to 100%). In 50 patients without CF (24M/26F, age range 6m to 12.5y) the median value of sweat Cl and conductivity were 15.5 and 30 mmol/L, respectively. All patients had conductivity values bellow 70 mmol/L (100% specificity; 95%CI: 92.9 to 100%). Nine hundred and eighteen tests were then performed in patients being investigated for CF but 180 had inadequate samples. Of the 738 tests performed with both techniques in 714 CF was ruled out, with median values of sweat Cl of 11 mmol/L (range: 3 to 137 mmol/L) and of conductivity of 25 mmol/L (range: 14 to 138 mmol/L). Twenty four patients had a diagnosis of CF presenting a median sweat Cl of 87 mmol/L (range: 54 to 132 mmol/L) and a median conductivity value of 103 mmol/L (range: 50 to 126 mmol/L). The ROC curve showed that with a conductivity value > 90 mmol/L sensitivity of 83.3%, specificity of 99.7%, PPV of 90.9% and NPV of 99.4% was obtained to diagnose CF. The best conductivity cut-off value to exclude CF was < 75 mmol/L (NPV=99.7%; IC95%:99.0-100%). Good agreement were observed between the tests (kappa: 0.934; IC95% 0.86 a 1.009; McNemar test: p=1.0000). The time spent to perform the tests was significantly lower with the simplified test (p<0.0001) and the cost was slightly lower with the conductivity test. CONCLUSIONS: sweat conductivity performed in patients with a known CF or non-CF diagnosis or randomly applied in subjects referred for a sweat test showed similar results as the classic test and could differentiate patients with or without CF. Conductivity test had a high sensitivity and specificity and good agreement was observed between the techniques. The time spent to perform the tests was lower with the simplified test, as well as the cost.

As infecções pneumocócicas são uma importante causa de morbi-mortalidade entre as crianças. Até 2000, era disponível apenas a vacina pneumocócica polissacarídica 23valente, de uso a partir dos 2 anos de idade. Essa vacina era recomendada para crianças com fibrose cística (FC) e para as asmáticas em uso de corticóide oral, dentre outras recomendações. A partir de 2000, licenciou-se a vacina pneumocócica conjugada 7valente, com grande impacto contra infecções causadas pelos sorotipos vacinais. Nos países onde as crianças não são universalmente vacinadas com essa vacina, as recomendações permanecem as mesmas. Atualmente, os adultos asmáticos estão incluídos nas recomendações para vacinação pneumocócica nos EUA. Há poucos estudos sobre o risco de doença pneumocócica em crianças asmáticas per si e naquelas com fibrose cística e sobre a resposta à vacina pneumocócica conjugada. Salienta-se que ainda não há um critério estabelecido para avaliar a resposta sorológica a essa vacina. Recentemente, foi sugerido o critério de 0,35mcg/ml por Elisa para se correlacionar com proteção para doença invasiva pneumocócica. Objetivou-se determinar a concentração dos anticorpos contra os sorotipos vacinais contidos na vacina pneumocócica conjugada 7valente em crianças com asma moderada em uso de corticóide inalatório e em crianças com fibrose cística; avaliando-as pelos critérios de 0,35mcg/ml, 1,3mcg/ml e aumento de 4 vezes o título pós em relação ao pré-vacinal, para cada sorotipo e para a vacina, considerando-se a positividade para 5 sorotipos. Foram avaliadas 18 crianças em cada grupo. A mediana da idade foi de 82,5m nas asmáticas e 69,5m naquelas com FC. Foi colhida amostra para sorologia pré-vacinação e outra após 2 doses da vacina conjugada. As concentrações de anticorpos para os sorotipos vacinais foram quantificadas pelo Elisa. Para 0,35mcg/ml de corte, a grande maioria nos dois grupos já era positiva à inclusão para os sorotipos vacinais e à vacina. Considerando-se o valor de 1,3mcg/ml, entre os que eram negativos, as crianças asmáticas responderam entre 66,7% (9V) e 100% (14), e as com FC, entre 50% (19F) e 100% (6B e 14); e, em relação à resposta vacinal para esse nível, as asmáticas apresentaram 81,8% de resposta, enquanto as com FC, 91,7%. Avaliando-se pelo aumento de 4 vezes o título pós em relação ao pré-vacinal, a melhor resposta aos sorotipos, nos asmáticos, foi de 33,3% (4, 6B, 14 e 18C), e a nos com FC, 61,1% para o 6B; em termos de resposta vacinal, obteve-se 16,7% e 44,4%, para as asmáticas e aquelas com FC, respectivamente. Não houve interferência da vacinação prévia com a vacina pneumocócica polissacarídica. As medianas dos títulos pós em relação aos pré-vacinais, para os sorotipos, nos dois grupos, apresentaram um aumento significante. Apesar de boa parte das crianças apresentarem uma positividade elevada à inclusão, aquelas que eram negativas tenderam a apresentar uma boa resposta à vacina. / Pneumococcal infections are an important morbi-mortality cause among children. Until 2000, it was only available the 23-valent polysaccharide pneumococcal vaccine for children over two years old. This vaccine was recommended for cystic fibrosis (CF) children and to asthmatics children in use of oral corticosteroids, among other recommendations. From 2000, it was licensed the 7-valent conjugated pneumococcal vaccine, with a great impact against the infections caused by the vaccine serotypes. In the countries that dont make a universally use of this vaccine for children, the recommendations remain the same. At the present time, asthmatic adults are included for the pneumococcal vaccine recommendations in the United States. There are few studies about pneumococcal disease risk with cystic fibrosis children and asthmatics, per si, and about the conjugated pneumococcal vaccine response. It points out that there are no a definitive criteria or evaluation established for the serology response for this vaccine. It was suggested, recently, that the level of 0,35mcg/ml, measured by ELISA, is adequate to correlate with the invasive pneumococcal disease protection. The goal of this study was to determine the antibodies concentration of the seven vaccine serotypes from 7-valent conjugated pneumococcal vaccine among children with moderate asthma in use of inhaled corticosteroids and with cystic fibrosis. It was considered the dosage 0,35mcg/ml and 1,3mcg/ml levels and the four-fold increase between pre- and post-immunization concentrations levels, to each serotype and to the vaccine (positivity for five serotypes or more) for positivity. Eighteen children were included in each study group. The age median was 82,5 months for the asthmatics and 69,5 months for the CF children. A blood sample was taken for pre-immunization serology and a second one after the second vaccine dose was given. The antibodies concentrations for the vaccine serotypes were measured by ELISA. Considering the 0,35mcg/ml levels, the majority of children, in both groups, was positive for vaccine serotypes and for the vaccine as well in the beginning. At the 1,3mcg/ml level, among the children with negative serology, asthmatic children responded between 66,7% (9V) and 100% (14), and those with CF, between 50% (19F) and 100% (6B e 14). Related to the vaccine response for this level, the asthmatics had a 81,8% response, while the CF childrens response was 91,7%. Evaluating for the four-fold increase between pre- and post-immunization concentrations, the best response observed for the vaccine serotypes was 33,3% (4, 6B, 14 e 18C) for the asthmatics. In the CF group the best result was 61,1% (6B). In terms of the vaccine response, it was observed that 16,7% and 44,4% were the results for both the asthmatics and CF group, respectively. The polysaccharide vaccine didnt interfere in the results. The medians of the pre- and post-immunization antibodies concentrations for the vaccine serotypes, in both groups, were significantly increased. Despite those children that were already positive for the criteria evaluated, at the first moment of the study, for those children that were negative, the majority had a positive serology towards the vaccination response.